A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: February 3, 2012
Last updated: April 24, 2015
Last verified: April 2015
This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pharmacoepidemiological Study on the Use of Arcoxia® Under Actual Conditions of Use in France

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Dose (in milligrams) of etoricoxib or celecoxib prescribed [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Number of participants with a given duration of prescription of etoricoxib or celecoxib use [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Number of participants with a given reason for prescribing etoricoxib or celecoxib [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of participants discontinuing treatment with etoricoxib or celecoxib for a particular reason [ Time Frame: Up to 12 months ] [ Designated as safety issue: Yes ]

Enrollment: 544
Study Start Date: June 2012
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Participants prescribed etoricoxib in routine clinical practice.
Celecoxib Group
Participants prescribed celecoxib in routine clinical practice.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants spontaneously consulting a general practitioner or rheumatologist and having agreed to take part in this study.

Inclusion Criteria:

  • Treatment-naive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib
  • Consent to take part in the study
  • Included in his/her physician's client base for at least 1 year

Exclusion Criteria:

  • Unable to receive follow-up over a year
  • Included in an interventional trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01572675     History of Changes
Other Study ID Numbers: 0663-148 
Study First Received: February 3, 2012
Last Updated: April 24, 2015
Health Authority: France: ANSM - French Health Products Safety Agency

Keywords provided by Merck Sharp & Dohme Corp.:

Additional relevant MeSH terms:
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016